One major challenge in targeting CAR T cells to patients with solid tumors is the limited homing of CAR T cells to solid tumors. The University of Colorado research group led by Dr Michael Verneris has developed a CAR construct to target CAR-T cells to IL-8 (CXCL8) producing target tumors. This chemokine is commonly expressed by tumors (brain, lung, GI tract, ovarian, prostate, etc.) and expression correlates with tumor grade, metastatic- and/or relapsed disease. The receptors for IL-8 (CXCL8) are CXCR1 and -2. These receptors are not typically expressed by T cells. Thus, the Verneris laboratory has made B7-H3 CAR T constructs that co-express either CXCR1, CXCR-2 or both CXCR- 1 and CXCR-2. These T-cells home to chemokine gradients and have better in vivo activity (in animal models). They also show superior cytotoxicity, cytokine production and metabolic changes that allow for alternative fuel utilization in the tumor microenvironment. B7H3 is absent on normal tissues (or present in negligible amounts), but is highly expressed on the above solid tumors. This PCT stage patented technology covers the use of the CAR not just on T cells, but also as an NK cell therapy, and the research group have published applications of the therapy, developed robust in vitro and in vivo models, including rodent xenograft models and in dogs with macroscopic pulmonary osteosarcaoma metastases and explored applications as both an allogenic and autologous therapy.